SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7514 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7514-7514 ◽

Author(s):

Nathan A. Pennell ◽

Joel W. Neal ◽

Jamie E. Chaft ◽

Christopher G. Azzoli ◽

Pasi A. Janne ◽

...

Keyword(s):

Phase Ii ◽

Egfr Mutation ◽

Phase Ii Trial ◽

Early Stage ◽

Multicenter Phase

Download Full-text

UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Hematological Oncology ◽

10.1002/hon.31_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

A. Pulsoni ◽

M. E. Tosti ◽

S. Ferrero ◽

S. Luminari ◽

A. Dondi ◽

...

Keyword(s):

Follicular Lymphoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Stage ◽

Multicenter Phase

Download Full-text

Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2− Early-stage Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2018.06.012 ◽

2018 ◽

Vol 18 (6) ◽

pp. 474-480 ◽

Author(s):

Takashi Kuwayama ◽

Seigo Nakamura ◽

Naoki Hayashi ◽

Toshimi Takano ◽

Koichiro Tsugawa ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Multicenter Phase

Download Full-text

UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Hematological Oncology ◽

10.1002/hon.30_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

A. Pulsoni ◽

M. E. Tosti ◽

S. Ferrero ◽

S. Luminari ◽

A. Dondi ◽

...

Keyword(s):

Follicular Lymphoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Stage ◽

Multicenter Phase

Download Full-text

P2.03-005 Overall Survival Results from a Prospective, Multicenter Phase II Trial of Low-Dose Erlotinib as Maintenance in NSCLC Harboring EGFR Mutation

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1256 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2129

Author(s):

S. Hirano ◽

G. Naka ◽

Y. Takeda ◽

M. Iikura ◽

T. Hiroishi ◽

...

Keyword(s):

Overall Survival ◽

Phase Ii ◽

Low Dose ◽

Egfr Mutation ◽

Phase Ii Trial ◽

Multicenter Phase

Download Full-text

An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer

Zeitschrift für Gastroenterologie ◽

10.1055/s-0030-1263569 ◽

2010 ◽

Vol 48 (08) ◽

Author(s):

M Moehler ◽

J Hartmann ◽

F Lordick ◽

S Al-Batran ◽

P Reimer ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Gastric Cancer ◽

Multicenter Phase

Download Full-text

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

Case Medical Research ◽

10.31525/ct1-nct04089904 ◽

2019 ◽

Author(s):

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Early Stage ◽

Gastroesophageal Adenocarcinoma

Download Full-text

Faculty Opinions recommendation of Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157701.617915 ◽

2009 ◽

Author(s):

John Newell-Price ◽

Miguel Debono

Keyword(s):

Phase Ii ◽

Cushing’S Disease ◽

Phase Ii Trial ◽

Somatostatin Analog ◽

Cushing's Disease ◽

Multicenter Phase

Download Full-text

Faculty Opinions recommendation of A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718113892.793485442 ◽

2013 ◽

Author(s):

Luca Persani

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Multicenter Phase ◽

Histologic Subtypes ◽

Metastatic Thyroid Cancer

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793486222 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text